Multihospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures by Aldeyab, M.A. et al.
Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures

Mamoon A. Aldeyab (PhD), 1* Michael J. Devine (MB BCH BAO, MPH, FFPH), 2 Peter Flanagan (MD FRCP), 3 Michael Mannion (MB FRCPsych), 3 Avril Craig (DPhil), 2 Michael G. Scott (PhD), 3 Stephan Harbarth (MD, MS), 4 Nathalie Vernaz (PharmD), 5 Elizabeth Davies (MB BCH BAO, FRCPath), 3 Jon S. Brazier (PhD), 6 Brian Smyth (MB BCH BAO, MSc, FRCP, FFPH), 7 James C. McElnay (PhD), 1 Brendan F. Gilmore (PhD), 8 Geraldine Conlon (MSc), 3 Fidelma A. Magee (BSc), 3 Feras W. Darwish Elhajji (MSc), 1 Shaunagh Small (BSc), 3 Collette Edwards (BSc), 3 Chris Funston (MSc FIBMS CSci), 3 Mary P. Kearney (MB BCH BAO, FRCPath). 3

1 Clinical and Practice Research Group, School of Pharmacy, Queen’s University Belfast, BT9 7BL Belfast, Northern Ireland, UK;
2 Northern Health and Social Services Board, County Hall, Ballymena, Northern Ireland -  currently Public Health Agency, Ballymena , Northern Ireland BT42 1QB;
3 Northern Health and Social Care Trust, Ballymena, BT43 6DA, Northern Ireland, UK;
4 Infection Control Program, University of Geneva Hospitals and Medical School, Geneva, Switzerland;
5 Pharmacy Department, University of Geneva Hospitals and Medical School, Geneva, Switzerland;
6 Anaerobe Reference Laboratory, Public Health Wales, Microbiology Cardiff, University Hospital of Wales, Cardiff;
7  HPA Communicable Disease Surveillance Centre (Northern Ireland)  - currently Public Health Agency, Belfast City Hospital, BT9 7AB;
8 Biomaterials & Drug Delivery Group, School of Pharmacy, Queen's University Belfast, BT9 7BL Belfast, Northern Ireland, UK.
*Corresponding author: Dr Mamoon Aldeyab, Clinical and Practice Research Group, School of Pharmacy, Queen’s University Belfast-BT9 7BL-UK. 
E-mail: maldeyab02@qub.ac.uk (​mailto:maldeyab02@qub.ac.uk​)
Telephone: +44 28 90972033
Fax: +44 28 90247794
Note: word count of the body text for this article = 4,032
Abstract
Objective: To report a large outbreak of Clostridium difficile infection (CDI, ribotype 027) between June 2007 and August 2008, describe infection control measures and evaluate the impact of restricting the use of fluoroquinolones in controlling the outbreak. 
Design, patients and setting: An outbreak investigation in three acute care hospitals of the Northern Health and Social Care Trust in Northern Ireland.
Interventions: Implementation of a series of CDI control measures, which targeted high-risk antibiotic agents (i.e. restriction of fluoroquinolones), infection control practices and environmental hygiene
Results: A total of 318 cases of CDI were identified during the outbreak, which was the result of the interaction between C. difficile 027 ribotype being introduced into the affected hospitals for the first time and other predisposing risk factors (ranging from host factors to suboptimal compliance with antibiotic guidelines and infection control policies). The 30-day all-cause mortality was 24.5%; however, CDI was the attributable cause of death for only 2.5% of the infected patients. Time-series analysis showed that restricting the use of fluoroquinolones was associated with a significant reduction in the incidence of CDI (coefficient= -0.054; lag time=4 months; P= 0.003). 
Conclusion: These findings provide additional evidence to support the value of antimicrobial stewardship as an essential element of multifaceted interventions to control CDI outbreaks. The present CDI outbreak was ended following the implementation of an action plan improving communication, antibiotic stewardship, infection control practices, environmental hygiene and surveillance.
Key words: Clostridium difficile, outbreak investigation, antibiotic stewardship, infection control practices, time-series analysis.
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As the present work is considered a case review and outbreak investigation, ethical and Trust’s research and development approval was not required; the study has been registered with the Trust's research and development department.
Setting and study period
The Trust consists of four acute hospitals (907 beds) and four rehabilitation and palliative care hospitals (141 beds). The investigation consisted of two components: (1) a description of the CDI outbreak and infection control measures applied during the outbreak (June 16, 2007-August 31, 2008), (2) an ecological retrospective analysis which involved collecting monthly data on the usage of antibiotics and the incidence of CDI over a five and a half year study period (January 2004- June 2009). The former component included only 3 affected acute hospitals (Antrim Area Hospital [411 beds], Mid-Ulster Hospital [124 beds], Whiteabbey Hospital [130 beds]) and 2 rehabilitation/palliative care facilities (Braid Valley Hospital [36 beds] and Moyle Hospital [45 beds]). The latter component only included the affected acute hospitals.
Microbiology and pharmacy data
The monthly incidence of CDI was obtained from the clinical microbiology information system over the study period. Data duplication was eliminated, by removing more than one positive C. difficile test from the same patient if the positive tests were ≤ 28 days apart, as this was considered as a single episode. Within the hospital laboratory, clinical samples were processed according to routine microbiology procedures. All C. difficile assays for toxins A and B in faeces from patients with colitis-like symptoms were performed in the microbiology laboratory at Antrim Area Hospital using an Enzyme-Linked Immunoabsorbant Assay (PremierTM). Isolates of putative C. difficile were referred to the Anaerobe Reference Laboratory at the University Hospital of Wales, Cardiff for confirmation and typing. 
Prior to December 2007, ribotyping was requested based on medical assessment of clinical severity. From the beginning of December 2007, all C. difficile toxin positive samples were cultured anaerobically and those yielding growth of putative C. difficile were sent for ribotyping. PCR ribotyping was performed according to the method described by others 12 and the banding patterns produced were assigned to the PCR ribotyping library.13 

Prior to January 2008, in accordance with government guidelines, the testing of faeces from all patients of 65 years of age and over with diarrhea was the routine practice. The testing of faeces for patients of ≥ 2 years of age and < 65 years of age was carried out at physician request; toxin assays were carried out twice a day. Following the declaration of the outbreak in January 2008, diarrheal stool from all patients of aged 12 years and older were tested; toxin assays were carried out twice a day and when requested by the physician.

For the purpose of this investigation CDI was defined as a toxin positive test plus diarrhoea (an increased number (2 or more) of watery/liquid stools [i.e. type 6 and 7 according to the Bristol Stool Scale] 14 that is greater than normal for the patient, over a period of 24 hours). Patients infected with C. difficile were classified as severe if any of the following criteria were present; white cell count (WCC) >1500/mm3; temperature >38.5°C; acutely rising blood creatinine (e.g. >50% increase above baseline); and evidence of severe colitis (abdominal signs, radiology). Clinical signs were obtained by retrospective chart review using a standardized form. Cases of CDI were classified as follows 15: (1) hospital-associated C.difficile disease was defined as any patient with CDI symptom onset more than 48 hours after admission to the hospital, or any patient with CDI symptom onset ≤ 48 hours after admission to a hospital provided that symptom onset was less than 4 weeks after the last discharge from a hospital, (2) community-associated C.difficile disease was defined as any patient with CDI symptom onset ≤ 48 hours after admission to a hospital, provided that symptom onset was more than 12 weeks after the previous discharge from a hospital, (3) Indeterminate C. difficle disease was defined as any case patient who did not fit any of the above criteria.

The following epidemiological case definition was used for the outbreak: patients with a positive C. difficile toxin test from 16 June 2007 with compatible symptoms, who were inpatients in the affected hospitals when the sample was taken. The case definition includes cases up to 31 August 2008. This case definition was chosen to include the first confirmed case of C. difficile ribotype 027, which occurred on 16 June 2007; the outbreak was declared over in August 2008. The criteria for declaring the end of the outbreak were: (1) a sustained reduction in the number of new cases of CDI each month to the level which could have been regarded as the Trust’s baseline before the outbreak commenced, (2) a reduction in the number of cases with ribotype 027 newly acquired in the hospital environment, (3) no evidence of case to case transmission, and (4) evidence of successful implementation of the agreed control measures.






The Trust had guidelines for the empirical treatment of all major clinical infectious syndromes.  In January 2008, the empirical use of fluoroquinolones was restricted with the exceptions of epidydimo-orchitis, prostatitis, pelvic inflammatory disease, orbital cellulitis, and cellulitis in patients with penicillin-allergy.  Otherwise, use of a restricted antibiotic required exemption by a medical consultant, with monitoring by the hospital pharmacy in consultation with the Consultant Medical Microbiologist.
Routine infection control practices
The Trust’s infection control policies were consistent with national and international guidelines, which included regular hand hygiene between every patient contact. All patients diagnosed with CDI were placed in single room or cohort contact isolation.  Detergent and water were used for general ward cleaning while detergent followed by 1,000 ppm hypochlorite solution was used for the isolation rooms on a daily basis and on discharge or transfer of the patient.
Infection control practices during the outbreak
An action plan addressing communication, infection control practices, clinical management, environmental hygiene and surveillance was agreed by the Outbreak Control Team (OCT).  Information leaflets on the nature of CDI and the measures to control it were issued to staff, patients and visitors. Patient care equipment and environmental cleaning in all patient care areas, which included general wards and isolation rooms, was enhanced by the introduction of an intensive cleaning including the use of vaporised hydrogen peroxide and chemical disinfection with a chlorine releasing agent.  In general wards, patient care equipment and the environment were cleaned daily and on patient discharge or transfer using a chlorine dioxide product in a one step process; in isolation areas cleaning took place twice daily and on discharge or transfer using a two step process of detergent followed by 1,000 ppm hypochlorite. An isolation ward with eight single rooms and four bays each containing four beds was designated for CDI patients. All CDI laboratory-confirmed cases and patients with a presumptive CDI who were unable to maintain personal hygiene were isolated; other presumptive CDI patients were placed in open wards, with contact precautions being applied, until laboratory-confirmation was received. A care bundle, the Saving Lives High Impact Intervention (HII) number 7 was reinforced Trust wide to control the spread of CDI.17 The latter identified five main key elements as being necessary to reduce the incidence of CDI: prudent antibiotic use, correct hand hygiene, environmental decontamination, personal protective equipment and isolation/cohort nursing.17 The Infection Control Team (ICT) monitored the care bundle with support from three senior nurses seconded from their normal duties. Hospital Site Implementation Teams (HSIT) comprising a senior manager, ward nursing and medical staff and Hotel Services were formed to ensure the OCT action plan was implemented. The Trust infection control policies were implemented in all clinical areas and there was an ongoing programme of audit of hand hygiene practices and environmental cleanliness. 

Mortality determination
Mortality was determined on the basis of the information provided by Northern Ireland Statistics and Research Agency (NISRA) from the General Register Office for registered deaths during the outbreak period.  This information is based on the Medical Certificate of Cause of Death (MCCD) which is completed by a Registered Medical Practitioner who has treated the deceased in the 28 days prior to death. 18 On the MCCD, the Cause of Death can be included in Part I (indicating that C. difficile was the disease or condition directly leading to death) or Part II of the certificate (indicating that C. difficile was significant condition contributing to death but not related to the disease or condition causing it).  

Statistical analysis








In the affected hospitals, a marked increase in CDI incidence rates was observed in late 2007 and early 2008 (Figure 1); the average annual CDI incidence rates per 100 bed-days, for the affected acute hospitals, from January 2004 to December 2008 were 0.05, 0.07, 0.08, 0.12, and 0.11, respectively. CDI average annual incidence rates per 100 bed-days for each affected acute hospital, from January 2004 to December 2008, were: Antrim Area Hospital (0.05, 0.06, 0.09, 0.13, and 0.10); Whiteabbey Hospital (0.05, 0.06, 0.07, 0.09, and 0.13); Mid-Ulster Hospital (0.06, 0.10, 0.06, 0.10, and 0.11). In 2007, the average fluoroquinolone use (DDDs/100 bed-days) for Antrim area hospital, Whiteabbey Hospital, and Mid-Ulster Hospital were 12, 13, and 9, respectively. In 2008 (following restricting the use of fluoroquinolone), the average fluoroquinolone use (DDDs/100 bed-days) for the latter hospitals were 2, 3, and 1, respectively. 
The median age of patients was 81 years with 84% of the affected patients aged over 65 years.  Of the 318 affected patients, the onset of illness was within two days of admission for 57 patients (18%). Of these 57 patients, 26 (8%) were discharged from a Northern Trust Hospital within 4 weeks prior to onset of CDI. A further 8 (3%) patients were discharged from a Northern Trust Hospital between 4 weeks and 12 weeks prior to onset of CDI. Twenty three of the cases (7%) whose onset of symptoms was within 48 hours of admission were not hospitalised in a Northern Trust hospital in the 12 weeks before the onset of CDI. General characteristics of the affected patients (n=318) during the outbreak period and a comparison of characteristics of C. difficile 027 infected patients versus non-027 C. difficile ribotypes infected patients are shown in Table 1 and Table 2 respectively. 

A total of 154 of the 318 patients with CDI had been identified as deceased due to all causes up to 21 October 2008. One of those patients who died within 30 days was not identified by MCCD, giving a total of 155 (48.7%) deaths. Details of mortality rates in relation to overall mortality, mortality within 30 days and mortality after admission are shown in Table 3. Comparative clinical outcomes (i.e. non severe/ severe) and 30-day mortality of patients identified with ribotype 027 versus other identified ribotypes are shown in Table 4. No statistically significant differences were observed. Of the 15 ribotype 027 cases identified as deceased within 30 days (Table 4), 3 had C. difficile mentioned on Part I of the MCCD and 8 had C. difficile mentioned on Part II; 4 had no mention of C. difficile on death certificate. Of the 19 non-ribotype 027 identified as deceased within 30 days (Table 4), 2 had C. difficile mentioned on Part I of the MCCD, 7 had C. difficile mentioned on Part II; 10 had no mention of C. difficile on death certificate.










Recent reports of CDI outbreaks of greater severity and significant mortality associated with C. difficile ribotype 027 have focused attention on the changing epidemiology of this pathogen. The objective of this research was to report (in line with recent recommendation on outbreak investigations) 20 a large multi hospital outbreak due to C. difficile ribotype 027 in Northern Ireland, to describe infection control practices and to evaluate the impact of restricting the use of fluoroquinolones to control the outbreak. The majority of patients affected during the outbreak were exposed to one or more risk factors such as: host factors, (for example, advanced age and co-morbidities),3, 21 exposure to factors that disrupt the normal protective intestinal microflora (i.e. broad-spectrum antibiotics), 22-24 the use of gastric-acid suppressive agents, 25-27  and poor infection control practices (relating to the healthcare environment, healthcare workers’ compliance with hand-hygiene, etc.). 3, 28 Auditing of the compliance for adequate environmental cleanliness and antibiotic stewardship, before the outbreak occurred, showed that these practices were sub-optimal. 29, 30

The analysis of the ribotyped C. difficile isolates (during the outbreak period) showed that ribotype 027 was the most frequently identified strain (41%), highlighting the predominance of this ribotype in the outbreak. 30-day all-cause mortality observed in this outbreak (24.5%) was similar to others. 31-33 However, CDI was the 30-day attributable cause of death for 2.5% of the C. difficile infected patients. Although a number of studies have reported on the contribution of 027 ribotype to greater disease severity and mortality,34-37 our analysis showed no statistically significant difference in the 30-day mortality and clinical severity between patients infected with ribotype 027 and patients infected with non-027 ribotypes. This findings could be related to the patients’ different susceptibility profiles, who were affected by exposure to one or more of the previously mentioned risk factors, impact of the isolation ward to maximise clinical management and experience. A single group of clinicians and nurses were looking after CDI patients in the designated isolation ward. This may have led to the development of high levels of skill in the clinical assessment and management of people with CDI and ability to react more quickly to the clinical impact of CDI ribotype 027 to mitigate its effect. Of note, 12% of the non-027 ribotyped isolates were C. difficile ribotype 078, an emerging strain which was reported as having similar mechanisms for toxins hyper-production as 027 ribotype. 2 The assessment of clinical severity between patients infected with C. difficile 027 and other ribotypes requires further investigation with a larger sample size to allow the construction of multivariate models, which should include other factors that may have influenced our findings, e.g. age, morbidity on admission and effects of 078 ribotype. Thus, a definitive conclusion in relation to the latter assessment was not possible and these findings must therefore be interpreted with caution.

The investigation showed temporal relationships between the use of certain antibiotic classes and the incidence of CDI. Restricting the use of fluoroquinolones was associated with a significant reduction in the incidence of CDI, confirming fluoroquinolones as high risk agents. 24, 38 In addition, the analysis showed that the use of amoxicillin-clavulanic acid and macrolides was also positively correlated with the incidence of CDI. However, second and third generation cephalosporins did not appear as significant variables in the model, since their use was already very low within the Trust. The control of antibiotics within the Northern Health and Social Care has been scrutinised over a long period of time. 39 The latter analysis led to more robust guidance on the use of antibiotics to be developed and introduced in the study site hospitals in 1995, with a significant revision in 1999 specifically to restrict the use of broad-spectrum cephalosporins in response to an outbreak of CDI, as there was strong association with the use of these agents. 40 All antibiotic policies were regularly reviewed and updated.
Importantly, it has been emphasised that a combined approach of optimal infection control practices with antimicrobial stewardship is required in order to interrupt transmission and successfully control CDI outbreaks. 24, 41, 42 The current CDI outbreak ended after the implementation of a series of controlling measures, which targeted high-risk antibiotic agents (i.e. restricting the use of fluoroquinolones), infection control practices and environmental hygiene; this was achieved through the extended ICT and HSIT ensuring ward staff understood their role in controlling the outbreak. The implementation of the infection control and environmental hygiene measures was uniform among the affected hospitals with the exception of the isolation ward which was only established in Antrim Area Hospital. This isolation ward received patients from all hospitals within the Trust when they were fit to be transferred; patients unfit for transfer were isolated in single rooms in their admitted hospitals. Auditing of the compliance for adequate environmental cleanliness 29 and antibiotic stewardship [data provided by the European Surveillance of Antimicrobial Consumption network (ESAC); May 2009 survey], following the declaration of the outbreak, showed a remarkable improvement in these practices. The ESAC 2009 survey results showed that compliance with the Antrim Area Hospital antibiotic guidelines was 70% , while a previous audit for compliance with the hospital guidelines in surgical wards (in 2006) showed a lower compliance rate (i.e. 31%). 30 Similarly, external audits of environmental cleanliness (January 2008) showed  that all hospitals within the Trust improved their compliance scores for adequate environmental cleanliness. Antrim Area Hospital scored 89% in January 2008 audit, while in a previous audit (January 2007), the hospital score was 77%. 29 These results may provide an indication that the implementation of the outbreak-controlling measures was successful. Nevertheless, as the emergence of CDI is multifactorial, it is difficult to determine the relative contributions made by infection control measures and antimicrobial stewardship. This remains an area that needs further investigation. 

The study has some limitations. Firstly, although analysis of data included both the Trust CDI nosocomial cases and other CDI cases, the percentage of patients who were not hospitalised in a Northern Trust hospital in the 12 weeks prior to onset of CDI was only 7% (Table 1). These  patients were included in the study as it was not possible to establish whether any of these patients had been in a hospital of another Trust in the 28 days before onset of CDI. However, it is unlikely that such a low percentage (7%) can influence the findings. Secondly, it was not possible to rule out the possibility that there had been unrecognised cases of CDI ribotype 027 before June 2007. Thirdly, the CDI-mortality was determined based on the Medical Certificate of Cause of Death (MCCD) which may lack accuracy and data completeness. The Trust addressed this issue from early in the outbreak by having an independent review of case notes of toxin positive patients who were known to have died in 2007 in the Trust (due to all causes) by two senior clinicians; one was an external gastroenterologist. C. difficile was reported as significant condition contributing to death in the MCCD more frequently than the reviewed case notes. The observed differences may have influenced the findings, however, such an error in completion of the MCCD is more likely to impact all C. difficile ribotypes rather than being selective for a specific ribotype. Following the declaration of the outbreak in 2008, the Trust reinforced guidance on completion of MCCD and established more robust measures to monitor deaths associated with CDI using direct reporting to a senior clinician and the reviewing Infection Control Prevention (IPC) team data.  The Trust would note that all reported figures are provisional pending the completion of the "Public Inquiry into the Outbreak of C. difficile in Northern Trust Hospitals". Finally, the assessment of the impact of restricting fluoroquinolones did not take into account the changes in infection control practices that took place as a result of the CDI outbreak. However, such parameters may contribute to 34% of the variance in CDI rates that was not explained by the final model.

In conclusion, the occurrence of this multi-hospital CDI outbreak was the result of the interaction between C. difficile 027 ribotype being introduced into the affected hospitals for the first time and other predisposing risk factors (ranging from host factors to less than optimal compliance with infection control and environmental hygiene hospital policies) which facilitated its spread. These findings provide additional evidence to support the value of antimicrobial stewardship as an essential element of multifaceted interventions to control CDI outbreaks. The CDI outbreak was controlled by the implementation of an action plan improving communication, antibiotic stewardship, infection control practices, environmental hygiene and surveillance.
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Table 1. General characteristics of patients with Clostridium difficile infection (CDI) during the outbreak period (June 16, 2007-August 31, 2008).
Characteristic 	No. (%) of patients
Median age in years (interquartile) [na=318]	81 (71-87)
> 65 years	266 (84%)
Male (n=318)	120 (38%)
Female/male (ratio)	198/120 (1.7:1)
Median length of stay in hospital in days (interquartile) [n=318]	36 (16-72)
Median length of stay in hospital prior to first positive CDI toxin test in days (interquartile) [n=318]	11 (2-32)
Median length of stay in hospital following first positive CDI toxin test to discharge in days (interquartile) [n=318]	19 (8-36)
Onset of illness within 2 days of admission [n=318]	57 (18%)
    Discharged from a Northern Trust hospital within 4 weeks prior to onset of CDI	26 (8%)
    Discharged from a Northern Trust hospital between 4 weeks and 12 weeks prior to onset of CDI	8 (3%)
    Patients were not hospitalised in  a Northern Trust hospital in the 12  weeks prior to onset of CDI b	23 (7%)
Median co-morbidity score at admission (interquartile) [n= 263] c	1 (0-2)
Type of ward admission [n=258]
   Medical	216 (84%)
   Surgical	37 (14%)
   ICU	5 (2%)
Normal residence  [n=258]
     Nursing or residential home	63 (24%)
     Long stay hospital facility	5 (2%)
     Own home	190 (74%)
Ribotype results [n=318]	
    Samples sent for ribotype [n=318] d	213 (67%)
    Failure to grow/not able to be ribotyped  [n=213]	39(18%)
    Number of ribotyped samples [n=213]	174(82%)
    Ribotype 027 [n=174]	71 (41%)
    None-027 ribotype identified [n=174]	103 (59%)
       Ribotype 001 	24 (14%)
       Ribotype 078 	20(12%)
       Others 	59 (34%)
Antibiotics within the previous 12 weeks to diagnosis [n=261]e	238(91%)
Proton pump Inhibitors within the previous 12 weeks to diagnosis [n=268]	160 (60%)
Gastrointestinal surgery within the previous 12 weeks to diagnosis [n=269]	14 (5%)
Immunosuppressive therapy  within the previous 12 weeks to diagnosis [n=263]	23 (9%)
Prolonged laxative therapy within the previous 12 weeks to diagnosis [n=259]	78(30%)
Admission to hospital within the previous 12 weeks to diagnosis [n=256]	132 (52%)
a n, number of patients; only completed/available records were included for each variable.b It was not possible to establish whether any of these patients had been in a hospital of another Trust in the 28 days before onset of CDI. c Co-morbidity was scored using the Charlson Index as described by others. 43d The ribotyping of all C. difficile isolates only started in late 2007/early 2008.e Mostly amoxicillin-clavulanic acid (145 patients; 56%), piperacillin-tazobactam (81 patients; 31%), macrolides (69 patients; 26%), and fluoroquinolones (46 patients; 18%).	

Table 2. Characteristics of patients with Clostridium difficile infection (CDI, ribotype 027) infection versus non-027 ribotypes C. difficile patients’ infection during the outbreak period (June 16, 2007-August 31, 2008).
Characteristic 	027-ribotype (n=67)	Non-027 ribotypes (n=95)
	No. (%) of patients
Median age in years (interquartile) 	82 (75-87)	82 (72-88)
Male	23 (34)	35 (37%)
Median length of stay in hospital in days (interquartile) 	37 (17-76)          	37 (25-81)
Median length of stay in hospital prior to onset of CDI in days (interquartile) 	10 (3-25)	12 (3-31)
Median length of stay in hospital following first onset of CDI to discharge (interquartile)	24 (9-55)	22 (10-42)
Median comorbidity score at admission (interquartile)                                [027-ribotype, n= 54; other ribotypes, n=74 ]	1 (0-2)	1 (1-3)
Normal residence  [027-ribotype, n= 40 ; non-027 ribotypes, n=73 ]		
   Nursing or Residential Home	10 (25%)	22 (30)
   Long stay Hospital Facility	1 (3%)	1 (1%)
   Own Home	29 (73%)	50 (69%)
Antibiotics within the previous 12 weeks to diagnosis                                   [027-ribotype, n= 45; non-027 ribotypes, n=76]	45 (100%)	71 (93%)
Proton Pump Inhibitors within the previous 12 weeks to diagnosis                  [027-ribotype, n= 44; non-027 ribotypes, n=78]	22 (50%)	41 (53%)
GI surgery within the previous 12 weeks to diagnosis                                    [027-ribotype, n= 45; non-027 ribotypes, n=78]	3 (7%)	5 (6%)
Immunosuppressive therapy Feeding within the previous 12 weeks to diagnosis [027-ribotype, n= 41; non-027 ribotypes, n=77]	4 (10%)	6 (8%)
Prolonged laxative therapy [027-ribotype, n= 39; non-027 ribotypes, n=75]	15 (38%)	20 (27%)
Admission to hospital within the previous 12 weeks to diagnosis                    [027-ribotype, n= 35; non-027 ribotypes, n=70 ]	19 (54%)	38 (54%)








Table 3.  Mortality rates of the affected patients during the Clostridium difficile infection (CDI) outbreak (June 16, 2007-August 31, 2008).

Variable (n=318)	Mortality within 30 days	Mortality after 30 days	Overall mortality*
	No. (%) of patients
 Total number of deceased cases attributed to all causes	78 (24.5%)	77 (24.2%)	155 (48.7%)
  Number of Clostridium difficile cases mentioned on MCCD**	38 (11.9%)	13 (4.0%)	51 (16.0%)
  Number of Clostridium difficile cases recorded in Part I of the MCCD	8 (2.5%)	5(1.5%)	13 (4.1%)
  Number of Clostridium difficile cases recorded in Part II of the MCCD 	30 (9.4%)	8 (2.5%)	38 (11.9%)
 * Overall mortality is the 30-day and the after-30 day mortality rates grouped together














Table 4. Clinical outcome and 30-day mortality of patients identified with Clostridium difficile infection (CDI, ribotype 027) versus other identified ribotypes during the outbreak period, June 16, 2007-August 31, 2008.
Variable	Ribotype 027	Non-027 ribotype	p Value**   א2
Clinical severity at date of first positive CDI sample [n*=144]			
   Non severe	34 (74%)	74 (76%)	0.836
   Severe	12 (26%)	24 (24%)	
Clinical severity at worst point during this episode [n=129]			
   Non severe	26 (67%)	68 (76%)	0.297
   Severe	13 (33%)	22 (24%)	
30-day mortality [n=162]			
   Alive 	52(78%)	76 (80%)	0.713
   Dead	15(22%)	19(20%)	
* n, number of patients; only completed/available records were included for each variable.


















Table 5. Estimated multivariate time series analysis model for the impact of restricting the use of fluoroquinolones on the monthly incidence of Clostridium difficile infection (CDI, R2= 0.66)

Term	Lag timea	Coefficient (SE)b	T-ratio	P-value
Fluoroquinolone use restriction	4	-0.054044 (0.017585)	-3.073	0.0033





  a Represents the delay necessary to observe the effect (in months).

  b Indicates the size and the direction of the effect.
  c AR, autoregressive term representing past incidence density of CDI.
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